Guillain-Barré Syndrome Following COVID-19 Vaccine: a case-report

Fakhari, Mohammad Sadegh; Poorsaadat, Leila; Mahmoodiyeh, Behnam

doi:10.22541/au.166255023.35571788/v1

Cited by 2 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Neurological disorders also counted a quarter of the investigated cases mostly with Guillain-Barré syndrome (32) and Bell's palsy caused (29) by AstraZeneca, Sinopharm and Sputnik vaccines. Although the most incidences were captured post-first dose, a 60year-old man presented Guillain-Barré syndrome 20 days after the Sinopharm booster shot (73). The correlation between Bell's palsy and vaccinations has been introduced previously such as influenza H1N1 monovalent vaccine and intranasal inactivated influenza vaccine (74,75).…”

Section: Discussionmentioning

confidence: 99%

A Landscape on Disorders Following Different COVID-19 Vaccination: A Systematic Review of Iranian Case Reports

Larijani¹,

Doroud²,

Banifazl³

et al. 2023

Preprint

View full text Add to dashboard Cite

Vaccination against SARS-CoV-2 has significantly contributed to the recent pandemic control. COVID-19 vaccines are available with different platforms and the primary clinical trials results presented acceptable safety profile of the approved vaccines. Nevertheless, the long-term assessment of the adverse events or rare conditions need to be investigated. The present systematic review, aimed at classification of Iranian case reports following COVID-19 immunization. To achieve this goal, the related published case reports were explored via PubMed, Web of Science and Google scholar according to PRISMA guideline and available up to 14th Dec, 2022. Out of 437 explored studies, the relevant data were fully investigated which totally led to 40 studies including 64 case reports with a new onset of a problem. The cases were then classified according to the various items such as the type of adverse event manifestations and COVID-19 vaccine. The reported COVID-19 vaccines in the studied cases included Sinopharm, AstraZeneca, and COVAXIN. The results showed that the adverse events presented in 8 different categories from which cutaneous problems accounted as the most prevalent manifestations (43.7%) in which rare diseases were also screened such as Steven-Johnson syndrome, Morphea and Toxic Epidermal Necrolysis. Notably, almost 60% of the cases had no comorbidities. Moreover, the obtained data revealed nearly half of the incidences occurred after the first dose of injection and the mean duration of improvement after the symptom onset was 18.72±24.69 days. 73% of all the cases were either significantly improved or fully recovered. Although the advantages of COVID-19 vaccination is undoubtedly significant, the high risk individuals including those with a history of serious disease or comorbidities immunodeficiency conditions should be vaccinated with the utmost caution.

show abstract

Section: Discussionmentioning

confidence: 99%

A Landscape on Disorders Following Different COVID-19 Vaccination: A Systematic Review of Iranian Case Reports

Larijani¹,

Doroud²,

Banifazl³

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…In 79.5% of the cases, GBS occurred following the first dose of vaccination [14]. GBS developed in six patients after the inactivated BBIBP-CorV [5,15,16]. Four presented following the first dose, one after the second, and the other after the third booster dose.…”

Section: Discussionmentioning

confidence: 99%

Guillain-Barré Syndrome Following the First Dose of Inactivated SARS-CoV-2 Vaccine, BBIBP-CorV

Wijekoon¹,

Sarathchandra²,

Siribaddana³

2023

Cureus

View full text Add to dashboard Cite

We present a case report of Guillain-Barré syndrome (GBS) following inactivated whole virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, BBIBP-CorV. A man presented with paresthesia in both upper and lower limbs with bifacial weakness, onset 18 days after receiving the first BBIBP-CorV vaccine. A bifacial palsy with a paresthesia variant of GBS was diagnosed, and the patient was treated with intravenous immunoglobulin, arresting the progression of neurological symptoms. Clinicians need to be aware of the possibility of GBS following vaccination with BBIBP-CorV, an inactivated SARS-CoV-2 vaccine.

show abstract

Guillain-Barré Syndrome Following COVID-19 Vaccine: a case-report

Cited by 2 publications

References 11 publications

A Landscape on Disorders Following Different COVID-19 Vaccination: A Systematic Review of Iranian Case Reports

A Landscape on Disorders Following Different COVID-19 Vaccination: A Systematic Review of Iranian Case Reports

Guillain-Barré Syndrome Following the First Dose of Inactivated SARS-CoV-2 Vaccine, BBIBP-CorV

Contact Info

Product

Resources

About